Robert Wagner

Robert Wagner

Auto-generated profile, based on publicly available information

Robert Wagner

Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University 1 , Düsseldorf, Germany

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2021 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
RWRobert Wagner
Robert Wagner
MHMartin Heni
Martin Heni
ATAdam Tabak
Adam Tabak
JMJürgen Machann
Jürgen Machann
FSFritz Schick
Fritz Schick
AFAndreas Fritsche
Andreas Fritsche

5 October 2023 in Nature Medicine
Verified
Journal Article
Open access
PDF file
DTDeirdre K. Tobias
Deirdre K. Tobias
JMJordi Merino
Jordi Merino
AAAbrar Ahmad
Abrar Ahmad
CACatherine Aiken
Catherine Aiken
JBJamie L. Benham
Jamie L. Benham
PFPaul W Franks
Paul W Franks
Precision medicine is part of the logical evolution of contemporary evidence-based medicine that seeks to reduce errors and optimize outcomes when making medical decisions and health recommendations. Diabetes affects hundreds of millions of people worldwide, many of whom will develop life-threatening complications and die prematurely. Precision medicine can potentially address this enormous problem by accounting for heterogeneity in the etiology, clinical presentation and pathogenesis of common forms of diabetes and risks of complications. This second international consensus report on precision diabetes medicine summarizes the findings from a systematic evidence review across the key pillars of precision medicine (prevention, diagnosis, treatment, prognosis) in four recognized forms of diabetes (monogenic, gestational, type 1, type 2). These reviews address key questions about the translation of precision medicine research into practice. Although not complete, owing to the vast literature on this topic, they revealed opportunities for the immediate or near-term clinical implementation of precision diabetes medicine; furthermore, we expose important gaps in knowledge, focusing on the need to obtain new clinically relevant evidence. Gaps include the need for common standards for clinical readiness, including consideration of cost-effectiveness, health equity, predictive accuracy, liability and accessibility. Key milestones are outlined for the broad clinical implementation of precision diabetes medicine.

20 October 2021 in Nature Reviews Endocrinology
Verified
Journal Article
Closed access
PDF file
RWRobert Wagner
Robert Wagner
SESabine S. Eckstein
Sabine S. Eckstein
HYHajime Yamazaki
Hajime Yamazaki
FGFelicia Gerst
Felicia Gerst
JMJürgen Machann
Jürgen Machann
MHMartin Heni
Martin Heni

13 November 2014 in Diabetes
Verified
Journal Article
Closed access
PDF file
MHMartin Heni
Martin Heni
RWRobert Wagner
Robert Wagner
SKStephanie Kullmann
Stephanie Kullmann
RVRalf Veit
Ralf Veit
HHHaliza Mat Husin
Haliza Mat Husin
AFAndreas Fritsche
Andreas Fritsche
Animal studies suggest that insulin action in the brain is involved in the regulation of peripheral insulin sensitivity. Whether this holds true in humans is unknown. Using intranasal application of insulin to the human brain, we studied the impacts of brain insulin action on whole-body insulin sensitivity and the mechanisms involved in this process. Insulin sensitivity was assessed by hyperinsulinemic-euglycemic glucose clamp before and after intranasal application of insulin and placebo in randomized order in lean and obese men. After insulin spray application in lean subjects, a higher glucose infusion rate was necessary to maintain euglycemia compared with placebo. Accordingly, clamp-derived insulin sensitivity index improved after insulin spray. In obese subjects, this insulin-sensitizing effect could not be detected. Change in the high-frequency band of heart rate variability, an estimate of parasympathetic output, correlated positively with change in whole-body insulin sensitivity after intranasal insulin. Improvement in whole-body insulin sensitivity correlated with the change in hypothalamic activity as assessed by functional magnetic resonance imaging. Intranasal insulin improves peripheral insulin sensitivity in lean but not in obese men. Furthermore, brain-derived peripheral insulin sensitization is associated with hypothalamic activity and parasympathetic outputs. Thus, the findings provide novel insights into the regulation of insulin sensitivity and the pathogenesis of insulin resistance in humans.

8 August 2017 in Diabetologia
Verified
Journal Article
Closed access
PDF file
FGFelicia Gerst
Felicia Gerst
RWRobert Wagner
Robert Wagner
GKGabriele Kaiser
Gabriele Kaiser
MPMadhura Panse
Madhura Panse
MHMartin Heni
Martin Heni
DSDorothea Siegel-Axel
Dorothea Siegel-Axel

15 April 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
SKStephanie Kullmann
Stephanie Kullmann
VVVera Valenta
Vera Valenta
RWRobert Wagner
Robert Wagner
OTOtto Tschritter
Otto Tschritter
JMJürgen Machann
Jürgen Machann
MHMartin Heni
Martin Heni
Brain insulin action regulates eating behavior and energy fluxes throughout the body. However, numerous people are brain insulin resistant. How brain insulin responsiveness affects long-term weight and body fat composition in humans is still unknown. Here we show that high brain insulin sensitivity before lifestyle intervention associates with a more pronounced reduction in total and visceral fat during the program. High brain insulin sensitivity is also associated with less regain of fat mass during a nine year follow-up. Cross-sectionally, strong insulin responsiveness of the hypothalamus associates with less visceral fat, while subcutaneous fat is unrelated. Our results demonstrate that high brain insulin sensitivity is linked to weight loss during lifestyle intervention and associates with a favorable body fat distribution. Since visceral fat is strongly linked to diabetes, cardiovascular risk and cancer, these findings have implications beyond metabolic diseases and indicate the necessity of strategies to resolve brain insulin resistance.